Life Sciences | Life Sciences Times

Tasca Therapeutics Launches with $52 Million Series A Financing

December 10, 2024

UnitedHealthcare CEO Shot Dead in New York City

December 5, 2024

Vertex Pharmaceuticals CEO Reshma Kewalramani Honored with the Lifetime Achievement Award 2024

November 21, 2024

THIS WEEK'S STORIES

MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas

December 16, 2024

Syncell Announces $15 Million Series A Funding

December 11, 2024

RevBio Receives Both FDA Approval to Expand its Clinical Trial and CMS Reimbursement for its Regenerative Bone Adhesive for Cranial Flap Fixation

December 12, 2024

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

Tag: Life Sciences

Most Read

VectorY Strengthens Leadership Team with Appointment of Jim Scibetta as New CEO

MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas

Pleno, Inc. Appoints Dr. Vik Vaz, M.D. as Chief Executive Officer & President to Drive Commercial Growth After Closing $25M Series B Funding

Turn Therapeutics Secures $75 Million Investment Commitment Tied to Public Listing

EDITOR PICKS

Tasca Therapeutics Launches with $52 Million Series A Financing

UnitedHealthcare CEO Shot Dead in New York City

Vertex Pharmaceuticals CEO Reshma Kewalramani Honored with the Lifetime Achievement Award 2024

THIS WEEK'S STORIES

MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas

Syncell Announces $15 Million Series A Funding

RevBio Receives Both FDA Approval to Expand its Clinical Trial and CMS Reimbursement for its Regenerative Bone Adhesive for Cranial Flap Fixation

POPULAR CATEGORY

ABOUT US

FOLLOW US